Benzamides
Aobchem N-(2-Furanylmethyl)benzamide | ≥95% | CAS 3952-30-5 | C12H11NO2 | 5g
N-(2-Furanylmethyl)benzamide | ≥95% | CAS 3952-30-5 | C12H11NO2 | 5g
Aobchem 5-Cyano-2-fluorobenzamide | ≥95% | CAS 916213-61-1 | C8H5FN2O | 1g
5-Cyano-2-fluorobenzamide | ≥95% | CAS 916213-61-1 | C8H5FN2O | 1g
Aobchem N-(2-Furanylmethyl)benzamide | ≥95% | CAS 3952-30-5 | C12H11NO2 | 500mg
N-(2-Furanylmethyl)benzamide | ≥95% | CAS 3952-30-5 | C12H11NO2 | 500mg
Cayman Chemical 3amino Benzamide
A PARP inhibitor (IC50 = 5.4 µM in C3H/10T1/2 mouse stem cells); inhibits spontaneous, as well as FGF2-induced, cell invasiveness of HUVECs at 50 µM; induces tubulogenesis and reduces FGF2-induced expression of UPA in HUVECs at 50 µM; reduces telomere length in HeLaS3 human cervical cancer cells and non-cancerous COM3 hamster cells
Aobchem 3-Bromo-4-chlorobenzamide | ≥95% | CAS 791137-22-9 | C7H5BrClNO | 1g
3-Bromo-4-chlorobenzamide | ≥95% | CAS 791137-22-9 | C7H5BrClNO | 1g
Aobchem 4-Bromo-3-chlorobenzamide | ≥97% | CAS 1228826-41-2 | C7H5BrClNO | 1g
4-Bromo-3-chlorobenzamide | ≥97% | CAS 1228826-41-2 | C7H5BrClNO | 1g
Aobchem 4-Bromo-3-chlorobenzamide | ≥97% | CAS 1228826-41-2 | C7H5BrClNO | 250mg
4-Bromo-3-chlorobenzamide | ≥97% | CAS 1228826-41-2 | C7H5BrClNO | 250mg
Aobchem 5-Bromo-2-chlorobenzamide | ≥95% | CAS 188774-55-2 | C7H5BrClNO | 1g
5-Bromo-2-chlorobenzamide | ≥95% | CAS 188774-55-2 | C7H5BrClNO | 1g
Ambeed Sodium tetrakis 3 5bis trifluo
Sodium tetrakis(3,5-bis(trifluoromethyl)phenyl)borate, 79060-88-1, 97%
Ambeed Sodium tetrakis 3 5bis trifluo
Sodium tetrakis(3,5-bis(trifluoromethyl)phenyl)borate, 79060-88-1, 97%
TARGETMOL CHEMICALS INC TAFAMIDIS 25MG
Also available in 5 mg 10 mg 50 mg 100 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Tafamidis (Fx-1006A) is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs. It binds to TTR with negative cooperativity (Kd1 3 nM; Kd2 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s 2.7-3.2 uM) under fibril-promoting denaturing and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 uM. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy. purity: 99%